Key Takeaways from the Cancer Cachexia Market Report<\/b><\/p>\n Discover which therapies are expected to grab the major cancer cachexia treatment market share @ Cancer Cachexia Market Report<\/b><\/a><\/p>\n Cancer Cachexia Overview<\/b><\/p>\n Cancer cachexia is a multifactorial wasting disorder commonly observed in advanced stages of cancer. It is characterized by a progressive depletion of skeletal muscle and fat, resulting in profound weakness. Unlike general malnutrition, cancer cachexia does not improve with nutritional support alone. The condition is largely driven by systemic inflammation, with cytokines, proteins released by both tumor and host cells, playing a central role. These inflammatory mediators disrupt normal metabolic processes, triggering appetite loss (anorexia), insulin resistance (reduced glucose utilization), and a metabolic shift favoring tissue breakdown (catabolism) over tissue synthesis. This leads to a persistent energy deficit, especially in aggressive cancers such as pancreatic, lung, and head and neck cancers.<\/p>\n Diagnosing cancer cachexia is challenging due to the absence of a single diagnostic marker, requiring a comprehensive evaluation. This includes nutritional assessment tools like the Patient-Generated Subjective Global Assessment (PG-SGA) or Mini Nutritional Assessment (MNA), body composition analysis through imaging methods like computed tomography (CT), the gold standard, or alternatives such as dual-energy X-ray absorptiometry (DXA) and bioelectrical impedance analysis (BIA), as well as muscle strength tests like handgrip dynamometry.\u00a0<\/p>\n Laboratory indicators such as low serum albumin and elevated C-reactive protein (CRP) can aid diagnosis but lack specificity. Composite scoring systems like the modified Glasgow Prognostic Score (mGPS) and the Cancer Cachexia Score (CASCO) offer a more holistic approach by integrating clinical, metabolic, and functional parameters to stage the condition and predict clinical outcomes.<\/p>\n Cancer Cachexia Epidemiology Segmentation<\/b><\/p>\n The cancer cachexia epidemiology section provides insights into the historical and current cancer cachexia\u00a0patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.<\/p>\n The cancer cachexia\u00a0market report\u00a0proffers epidemiological analysis for the study period 2020\u20132034 in the 7MM segmented into:<\/p>\n Cancer Cachexia Treatment Market\u00a0<\/b><\/p>\n Progestational agents like MEGACE (megestrol) and medroxyprogesterone<\/b> are known to stimulate appetite and promote weight gain in individuals suffering from anorexia and cachexia. A randomized, prospective clinical study comparing megestrol (800 mg\/day) with dexamethasone (0.75 mg four times daily) found that both drugs had similar effects on enhancing appetite. However, megestrol was more frequently associated with thromboembolic complications, whereas dexamethasone was linked to side effects such as muscle weakness, Cushingoid appearance, and peptic ulcers.<\/p>\n Although corticosteroids and progestational<\/b> agents <\/b>have shown effectiveness in treating cancer-related anorexia and cachexia, they generally do not produce significant long-term benefits for most patients. As a result, alternative interventions, including enteral and parenteral nutrition, have been widely explored. In January 2021, Ono Pharmaceutical’s ADLUMIZ (Anamorelin)<\/b> was approved in Japan for the treatment of cancer cachexia in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).<\/p>\n Cytokine-targeted therapies have also been investigated. These therapies affect a range of tissues, including bone marrow, muscle, liver, fat, endothelial cells, and neurons, triggering complex biological responses that contribute to the muscle and weight loss seen in cachexia. Key cytokines implicated include tumor necrosis factor (TNF)-\u03b1, interleukins IL-1 and IL-6, and interferon-\u03b3 (IFN-\u03b3). These molecules share similar metabolic roles and often act in a coordinated or synergistic manner. Therefore, treatment strategies have focused on inhibiting either their production or their downstream effects.<\/p>\n To know more about cancer cachexia\u00a0treatment guidelines, visit @ Cancer Cachexia Treatment Options<\/b><\/a><\/p>\n Cancer Cachexia Pipeline Therapies and Key Companies<\/b><\/p>\n Discover more about cancer cachexia drugs in development\u00a0@ Cancer Cachexia Clinical Trials<\/b><\/a>\u00a0<\/p>\n Cancer Cachexia Market Dynamics<\/b><\/p>\n The cancer cachexia market dynamics are expected to change in the coming years. Cancer cachexia affects a significant portion of late-stage cancer patients<\/b>, creating a strong demand for effective therapies and presenting a valuable opportunity for companies to develop treatments, given the current lack of options and limited market competition<\/b>.<\/p>\n Furthermore, potential therapies are being investigated for the treatment of cancer cachexia, and it is safe to predict that the treatment space will significantly impact the cancer cachexia\u00a0market during the forecast period. Moreover, the anticipated introduction of emerging therapies<\/b> with improved efficacy and a further improvement in the diagnosis rate<\/b> are expected to drive the growth of the cancer cachexia\u00a0market in the 7MM.<\/p>\n However, several factors may impede the growth of the cancer cachexia\u00a0market. Studies have shown that cancer patients with cachexia respond poorly to chemotherapy, face a higher risk of infection, and have reduced survival<\/b>, with mortality rates ranging from 0\u201380%, and at least 30% of cancer patients<\/b> die from cachexia rather than the cancer itself.<\/p>\n Moreover, cancer cachexia\u00a0treatment poses a significant economic burden<\/b> and disrupts patients’ overall well-being and QOL. Furthermore, the cancer cachexia market growth may be offset by failures and discontinuation of emerging therapies<\/b>, unaffordable pricing<\/b>, market access and reimbursement issues<\/b>, and a shortage of healthcare specialists<\/b>. In addition, the undiagnosed, unreported cases and the unawareness<\/b> about the disease may also impact the cancer cachexia market growth.<\/p>\n Cancer Cachexia Market Report Metrics<\/b><\/p>\n<\/td>\n Details<\/b><\/p>\n<\/td>\n<\/tr>\n Study Period<\/p>\n<\/td>\n 2020\u20132034<\/p>\n<\/td>\n<\/tr>\n Coverage<\/p>\n<\/td>\n 7MM [The United States, the EU4 (Germany, France, Italy, and Spain) and The United Kingdom, and Japan].<\/p>\n<\/td>\n<\/tr>\n Cancer Cachexia Market CAGR<\/p>\n<\/td>\n 8.9\u00a0%<\/p>\n<\/td>\n<\/tr>\n Cancer Cachexia Market Size in 2024<\/p>\n<\/td>\n USD 475 Million<\/p>\n<\/td>\n<\/tr>\n Key Cancer Cachexia Companies<\/p>\n<\/td>\n Pfizer, Actimed Therapeutics, Endevica Bio, AVEO Oncology (an LG Chem company), Helsinn Healthcare, Ono Pharmaceutical, and others<\/p>\n<\/td>\n<\/tr>\n Key Pipeline Cancer Cachexia Therapies<\/p>\n<\/td>\n Ponsegromab (PF-06946860), S-pindolol benzoate (ACM-001.1; MT-102), TCMCB07, Rilogrotug (AV-380), ADLUMIZ, and others<\/p>\n<\/td>\n<\/tr>\n Scope of the <\/b>Cancer Cachexia<\/b>\u00a0Market Report<\/b><\/p>\n Download the report to understand which factors are driving cancer cachexia\u00a0market trends\u00a0@\u00a0Cancer Cachexia Drug Treatment<\/b><\/a><\/p>\n Table of Contents<\/b><\/p>\n 1<\/p>\n<\/td>\n Key Insights<\/p>\n<\/td>\n<\/tr>\n 2<\/p>\n<\/td>\n Report Introduction<\/p>\n<\/td>\n<\/tr>\n 3<\/p>\n<\/td>\n Cancer Cachexia Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n 3.1<\/p>\n<\/td>\n Market Share (%) Distribution by Therapies in the 7MM in 2024<\/p>\n<\/td>\n<\/tr>\n 3.2<\/p>\n<\/td>\n Market Share (%) Distribution by Therapies in the 7MM in 2034<\/p>\n<\/td>\n<\/tr>\n 4<\/p>\n<\/td>\n Executive Summary<\/p>\n<\/td>\n<\/tr>\n 5<\/p>\n<\/td>\n Key Events<\/p>\n<\/td>\n<\/tr>\n 6<\/p>\n<\/td>\n Disease Background and Overview<\/p>\n<\/td>\n<\/tr>\n 6.1<\/p>\n<\/td>\n Introduction<\/p>\n<\/td>\n<\/tr>\n 6.2<\/p>\n<\/td>\n Causes and Risk Factors<\/p>\n<\/td>\n<\/tr>\n 6.3<\/p>\n<\/td>\n Pathophysiology<\/p>\n<\/td>\n<\/tr>\n 6.3.1<\/p>\n<\/td>\n Role of Pain in the Pathophysiology of Cancer Cachexia<\/p>\n<\/td>\n<\/tr>\n 6.4<\/p>\n<\/td>\n Clinical Manifestations<\/p>\n<\/td>\n<\/tr>\n 6.5<\/p>\n<\/td>\n Laboratory Manifestations<\/p>\n<\/td>\n<\/tr>\n 6.6<\/p>\n<\/td>\n Staging<\/p>\n<\/td>\n<\/tr>\n 6.7<\/p>\n<\/td>\n Diagnosis<\/p>\n<\/td>\n<\/tr>\n 6.7.1<\/p>\n<\/td>\n Differential Diagnosis<\/p>\n<\/td>\n<\/tr>\n 6.7.2<\/p>\n<\/td>\n Diagnostic Algorithm<\/p>\n<\/td>\n<\/tr>\n 6.7.3<\/p>\n<\/td>\n Diagnostic Guidelines and Recommendations<\/p>\n<\/td>\n<\/tr>\n 6.8<\/p>\n<\/td>\n Treatment and Management<\/p>\n<\/td>\n<\/tr>\n 6.8.1<\/p>\n<\/td>\n Treatment Algorithm<\/p>\n<\/td>\n<\/tr>\n 6.8.2<\/p>\n<\/td>\n Treatment Guidelines and Recommendations<\/p>\n<\/td>\n<\/tr>\n 7<\/p>\n<\/td>\n Methodology<\/p>\n<\/td>\n<\/tr>\n 8<\/p>\n<\/td>\n Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n 8.1<\/p>\n<\/td>\n Key Findings<\/p>\n<\/td>\n<\/tr>\n 8.2<\/p>\n<\/td>\n Assumptions and Rationale: The 7MM<\/p>\n<\/td>\n<\/tr>\n 8.2.1<\/p>\n<\/td>\n Diagnosed Prevalent Cases of Cancer Cachexia<\/p>\n<\/td>\n<\/tr>\n 8.2.2<\/p>\n<\/td>\n Gender-specific Cases of Cancer Cachexia<\/p>\n<\/td>\n<\/tr>\n 8.2.3<\/p>\n<\/td>\n Tumor Type-specific Cases of Cancer Cachexia<\/p>\n<\/td>\n<\/tr>\n 8.2.4<\/p>\n<\/td>\n Age-specific Cases of Cancer Cachexia<\/p>\n<\/td>\n<\/tr>\n 8.3<\/p>\n<\/td>\n Total Diagnosed Prevalent Cases of Cancer Cachexia in the 7MM<\/p>\n<\/td>\n<\/tr>\n 8.4<\/p>\n<\/td>\n The US<\/p>\n<\/td>\n<\/tr>\n 8.4.1<\/p>\n<\/td>\n Total Diagnosed Prevalent Cases of Cancer Cachexia in the US<\/p>\n<\/td>\n<\/tr>\n 8.4.2<\/p>\n<\/td>\n Gender-specific Cases of Cancer Cachexia in the US<\/p>\n<\/td>\n<\/tr>\n 8.4.3<\/p>\n<\/td>\n Tumor Type-specific Cases of Cancer Cachexia in the US<\/p>\n<\/td>\n<\/tr>\n 8.4.4<\/p>\n<\/td>\n Age-specific Cases of Cancer Cachexia in the US<\/p>\n<\/td>\n<\/tr>\n 8.5<\/p>\n<\/td>\n EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 8.5.1<\/p>\n<\/td>\n Total Diagnosed Prevalent Cases of Cancer Cachexia in EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 8.5.2<\/p>\n<\/td>\n Gender-specific Cases of Cancer Cachexia in EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 8.5.3<\/p>\n<\/td>\n Tumor Type-specific Cases of Cancer Cachexia in EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 8.5.4<\/p>\n<\/td>\n Age-specific Cases of Cancer Cachexia in EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 8.6<\/p>\n<\/td>\n Japan<\/p>\n<\/td>\n<\/tr>\n 8.6.1<\/p>\n<\/td>\n Total Diagnosed Prevalent Cases of Cancer Cachexia in Japan<\/p>\n<\/td>\n<\/tr>\n 8.6.2<\/p>\n<\/td>\n Gender-specific Cases of Cancer Cachexia in Japan<\/p>\n<\/td>\n<\/tr>\n 8.6.3<\/p>\n<\/td>\n Tumor Type-specific Cases of Cancer Cachexia in Japan<\/p>\n<\/td>\n<\/tr>\n 8.6.4<\/p>\n<\/td>\n Age-specific Cases of Cancer Cachexia in Japan<\/p>\n<\/td>\n<\/tr>\n 9<\/p>\n<\/td>\n Patient Journey<\/p>\n<\/td>\n<\/tr>\n 10<\/p>\n<\/td>\n Marketed Drugs<\/p>\n<\/td>\n<\/tr>\n 10.1<\/p>\n<\/td>\n ADLUMIZ (anamorelin hydrochloride): Helsinn Healthcare\/Ono Pharmaceutical<\/p>\n<\/td>\n<\/tr>\n 10.1.1<\/p>\n<\/td>\n Product Description<\/p>\n<\/td>\n<\/tr>\n 10.1.2<\/p>\n<\/td>\n Regulatory Milestones<\/p>\n<\/td>\n<\/tr>\n 10.1.3<\/p>\n<\/td>\n Other Developmental Activities<\/p>\n<\/td>\n<\/tr>\n 10.1.4<\/p>\n<\/td>\n Clinical Trials Information<\/p>\n<\/td>\n<\/tr>\n 10.1.5<\/p>\n<\/td>\n Safety and Efficacy<\/p>\n<\/td>\n<\/tr>\n List to be continued in the final report\u2026.<\/p>\n<\/td>\n<\/tr>\n 11<\/p>\n<\/td>\n Emerging Drugs<\/p>\n<\/td>\n<\/tr>\n 11.1<\/p>\n<\/td>\n Key Cross Competition<\/p>\n<\/td>\n<\/tr>\n 11.2<\/p>\n<\/td>\n Ponsegromab (PF-06946860): Pfizer<\/p>\n<\/td>\n<\/tr>\n 11.2.1<\/p>\n<\/td>\n Drug Description<\/p>\n<\/td>\n<\/tr>\n 11.2.2<\/p>\n<\/td>\n Other Developmental Activities<\/p>\n<\/td>\n<\/tr>\n 11.2.3<\/p>\n<\/td>\n Clinical Trials Information<\/p>\n<\/td>\n<\/tr>\n 11.2.4<\/p>\n<\/td>\n Safety and Efficacy<\/p>\n<\/td>\n<\/tr>\n 11.2.5<\/p>\n<\/td>\n Analysts’ View<\/p>\n<\/td>\n<\/tr>\n 11.3<\/p>\n<\/td>\n S-pindolol benzoate (ACM-001.1; MT-102): Actimed Therapeutics<\/p>\n<\/td>\n<\/tr>\n 11.3.1<\/p>\n<\/td>\n Drug Description<\/p>\n<\/td>\n<\/tr>\n 11.3.2<\/p>\n<\/td>\n Other Developmental Activities<\/p>\n<\/td>\n<\/tr>\n 11.3.3<\/p>\n<\/td>\n Clinical Trials Information<\/p>\n<\/td>\n<\/tr>\n 11.3.4<\/p>\n<\/td>\n Safety and Efficacy<\/p>\n<\/td>\n<\/tr>\n 11.3.5<\/p>\n<\/td>\n Analysts’ View<\/p>\n<\/td>\n<\/tr>\n 11.4<\/p>\n<\/td>\n TCMCB07: Endevica Bio<\/p>\n<\/td>\n<\/tr>\n 11.4.1<\/p>\n<\/td>\n Drug Description<\/p>\n<\/td>\n<\/tr>\n 11.4.2<\/p>\n<\/td>\n Other Developmental Activities<\/p>\n<\/td>\n<\/tr>\n 11.4.3<\/p>\n<\/td>\n Clinical Trials Information<\/p>\n<\/td>\n<\/tr>\n 11.4.4<\/p>\n<\/td>\n Safety and Efficacy<\/p>\n<\/td>\n<\/tr>\n 11.5<\/p>\n<\/td>\n Rilogrotug (AV-380): AVEO Oncology (an LG Chem company)<\/p>\n<\/td>\n<\/tr>\n 11.5.1<\/p>\n<\/td>\n Drug Description<\/p>\n<\/td>\n<\/tr>\n 11.5.2<\/p>\n<\/td>\n Other Developmental Activities<\/p>\n<\/td>\n<\/tr>\n 11.5.3<\/p>\n<\/td>\n Clinical Trials Information<\/p>\n<\/td>\n<\/tr>\n List to be continued in the final report\u2026.<\/p>\n<\/td>\n<\/tr>\n 12<\/p>\n<\/td>\n Cancer Cachexia \u2013 7MM Market Analysis<\/p>\n<\/td>\n<\/tr>\n 12.1<\/p>\n<\/td>\n Key Findings<\/p>\n<\/td>\n<\/tr>\n 12.2<\/p>\n<\/td>\n Key Market Forecast Assumptions<\/p>\n<\/td>\n<\/tr>\n 12.2.1<\/p>\n<\/td>\n Cost Assumptions and Rebates<\/p>\n<\/td>\n<\/tr>\n 12.2.2<\/p>\n<\/td>\n Pricing Trends<\/p>\n<\/td>\n<\/tr>\n 12.2.3<\/p>\n<\/td>\n Analogue Assessment<\/p>\n<\/td>\n<\/tr>\n 12.2.4<\/p>\n<\/td>\n Launch Year and Therapy Uptake<\/p>\n<\/td>\n<\/tr>\n 12.3<\/p>\n<\/td>\n Market Outlook<\/p>\n<\/td>\n<\/tr>\n 12.4<\/p>\n<\/td>\n Attribute Analysis<\/p>\n<\/td>\n<\/tr>\n 12.5<\/p>\n<\/td>\n Total Market Size of Cancer Cachexia in the 7MM<\/p>\n<\/td>\n<\/tr>\n 12.6<\/p>\n<\/td>\n Market Size of Cancer Cachexia by Therapies in the 7MM<\/p>\n<\/td>\n<\/tr>\n 12.7<\/p>\n<\/td>\n The US<\/p>\n<\/td>\n<\/tr>\n 12.7.1<\/p>\n<\/td>\n Total Market Size of Cancer Cachexia in the US<\/p>\n<\/td>\n<\/tr>\n 12.7.2<\/p>\n<\/td>\n Market Size of Cancer Cachexia by Therapies in the US<\/p>\n<\/td>\n<\/tr>\n 12.8<\/p>\n<\/td>\n EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 12.8.1<\/p>\n<\/td>\n Total Market Size of Cancer Cachexia in EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 12.8.2<\/p>\n<\/td>\n Market Size of Cancer Cachexia by Therapies in EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 12.9<\/p>\n<\/td>\n Japan<\/p>\n<\/td>\n<\/tr>\n 12.9.1<\/p>\n<\/td>\n Total Market Size of Cancer Cachexia in Japan<\/p>\n<\/td>\n<\/tr>\n 12.9.2<\/p>\n<\/td>\n Market Size of Cancer Cachexia by Therapies in Japan<\/p>\n<\/td>\n<\/tr>\n 13<\/p>\n<\/td>\n Key Opinion Leaders’ Views<\/p>\n<\/td>\n<\/tr>\n 14<\/p>\n<\/td>\n Unmet Needs<\/p>\n<\/td>\n<\/tr>\n 15<\/p>\n<\/td>\n SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n 16<\/p>\n<\/td>\n Market Access and Reimbursement<\/p>\n<\/td>\n<\/tr>\n 16.1<\/p>\n<\/td>\n The United States<\/p>\n<\/td>\n<\/tr>\n 16.1.1<\/p>\n<\/td>\n CMS<\/p>\n<\/td>\n<\/tr>\n 16.2<\/p>\n<\/td>\n EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 16.2.1<\/p>\n<\/td>\n Germany<\/p>\n<\/td>\n<\/tr>\n 16.2.2<\/p>\n<\/td>\n France<\/p>\n<\/td>\n<\/tr>\n 16.2.3<\/p>\n<\/td>\n Italy<\/p>\n<\/td>\n<\/tr>\n 16.2.4<\/p>\n<\/td>\n Spain<\/p>\n<\/td>\n<\/tr>\n 16.2.5<\/p>\n<\/td>\n The United Kingdom<\/p>\n<\/td>\n<\/tr>\n 16.3<\/p>\n<\/td>\n Japan<\/p>\n<\/td>\n<\/tr>\n 16.3.1<\/p>\n<\/td>\n MHLW<\/p>\n<\/td>\n<\/tr>\n 17<\/p>\n<\/td>\n Appendix<\/p>\n<\/td>\n<\/tr>\n 17.1<\/p>\n<\/td>\n Acronyms and Abbreviations<\/p>\n<\/td>\n<\/tr>\n 17.2<\/p>\n<\/td>\n Bibliography<\/p>\n<\/td>\n<\/tr>\n 17.3<\/p>\n<\/td>\n Report Methodology<\/p>\n<\/td>\n<\/tr>\n 18<\/p>\n<\/td>\n DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n 19<\/p>\n<\/td>\n Disclaimer<\/p>\n<\/td>\n<\/tr>\n 20<\/p>\n<\/td>\n About DelveInsight<\/p>\n<\/td>\n<\/tr>\n Related Reports<\/b><\/p>\n TNF-alpha Inhibitors Market<\/b><\/a><\/p>\n TNF-alpha Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast <\/b>\u2013\u00a02034 <\/b>report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key TNF-alpha inhibitors\u00a0companies, including AbbVie, Amgen, Johnson & Johnson (through Janssen Biotech), UCB, Pfizer, Merck, Samsung Bioepis, Biogen, Takeda Pharmaceutical Company,<\/b> among others.<\/p>\n Cancer Cachexia\u00a0Pipeline<\/b><\/a><\/p>\n Cancer Cachexia\u00a0Pipeline Insight \u2013\u00a02025<\/b>\u00a0report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cancer cachexia\u00a0companies, including Actimed Therapeutics Ltd, Pfizer, AVEO Pharmaceuticals, Inc., NGM Biopharmaceuticals, Endevica Bio, CSPC Pharmaceutical Group Limited, Caelus Health, <\/b>among others.<\/p>\n Cancer Anorexia\u00a0Market<\/b><\/a><\/p>\n Cancer Anorexia\u00a0Market Insights, Epidemiology, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cancer anorexia\u00a0companies, including Helsinn Healthcare, Artelo Biosciences, NGM Biopharmaceuticals, <\/b>among others.<\/p>\n Cancer Cachexia\u00a0Pipeline<\/b><\/a><\/p>\n Cancer Cachexia\u00a0Pipeline Insight \u2013\u00a02025<\/b>\u00a0report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cachexia\u00a0companies, including Tvardi Therapeutics, TMS Co. Ltd, RaQualia Pharma, Pfizer, Pephexia Therapeutics, Oncocross, NGM Biopharmaceuticals, MGC Pharmaceuticals, Keros Therapeutics, Incyte Corporation, ImmunoForge, Immuneering Corporation, Green Cross Wellbeing, GlaxoSmithKline, Faraday Pharmaceuticals, Extend Biosciences, Energenesis Biomedica, Endevica Bio, CNBX Pharmaceuticals, CatalYm, Caelus Health, AVEO Oncology, Artelo Biosciences, Aphios Corporation, AliveGen, AEterna Zentaris, Actimed Therapeutics, AAVogen, <\/b>among others.<\/p>\n About\u00a0DelveInsight<\/b><\/p>\n DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve.<\/b><\/p>\n Contact Us<\/b><\/p>\n Shruti Thakur \n
\n
\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
[email\u00a0protected]<\/a>
+14699457679
www.delveinsight.com<\/a><\/p>\n
![\"\"](\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO26744&Transmission_Id=202507091731PR_NEWS_USPR_____IO26744&DateId=20250709\")
<\/p>\n","protected":false},"excerpt":{"rendered":"The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of…\n","protected":false},"author":3,"featured_media":28217,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[64,24334,31632,4629,39234,135,31633,152,67,132,68],"class_list":{"0":"post-52470","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-delveinsight-business-research","10":"tag-health-care-hospitals","11":"tag-llp","12":"tag-market-research-reports","13":"tag-markets","14":"tag-medical-pharmaceuticals","15":"tag-pharmaceuticals","16":"tag-united-states","17":"tag-unitedstates","18":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114825584049106829","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/52470","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=52470"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/52470\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/28217"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=52470"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=52470"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=52470"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}